These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37493495)

  • 1. Catechol-O-methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease.
    Poewe W
    Eur J Neurol; 2023 Nov; 30 Suppl 2():9-14. PubMed ID: 37493495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo
    Reichmann H
    Eur J Neurol; 2023 Nov; 30 Suppl 2():15-20. PubMed ID: 37489705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).
    Solla P; Cannas A; Marrosu F; Marrosu MG
    Neuropsychiatr Dis Treat; 2010 Sep; 6():483-90. PubMed ID: 20856911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA
    Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entacapone. A review of its use in Parkinson's disease.
    Holm KJ; Spencer CM
    Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC; Hauser RA
    Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entacapone.
    Chong BS; Mersfelder TL
    Ann Pharmacother; 2000 Sep; 34(9):1056-65. PubMed ID: 10981253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.